Observational studyBMC infectious diseases2025
Trajectories of persisting Covid- 19 symptoms up to 24 months after acute infection: findings from the Predi-Covid cohort study.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04380987 (Luxembourg Cohort of Positive Patients for COVID-19), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis
Who cites it
9 citing papers in PubMed.
- Posterior Circulation Ischemic Stroke Occurring After ChAdOx1 nCoV-19/AZD1222 Vaccination Without Evidence of Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Case Report and Focused Narrative Review.Journal of clinical medicine · 2026Review
- Symptom Trajectories and Long-Term Sequelae of COVID-19: A Matched Case-Control Study with Population-Based Controls.Journal of clinical medicine · 2026Article
- Clinical Utility of SARS-CoV-2 Antibody Titers in the Management of Patients With Long COVID Infected With the Omicron Variant.British journal of biomedical science · 2026Observational
- Editorial: The influence of SARS-CoV-2 infection and long-COVID on the incidence of viral coinfection.Frontiers in immunology · 2026Article
- Long COVID Prevalence and Risk Factors: A Systematic Review and Meta-Analysis of Prospective Cohort Studies.Biomedicines · 2025Review
- Long-term symptoms after SARS-CoV-2 infection in a cohort of healthcare workers in Qatar.BMC infectious diseases · 2025Article
- Living With Persistent Respiratory Symptoms of Long COVID: Qualitative Study Among Brazilian Adults 12 Months After Acute Infection.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Factors associated with persistence or recovery from long COVID 6 months post-SARS-CoV-2 infection.Epidemiology and infection · 2025Article
- Symptomatic Trends and Time to Recovery for Long COVID Patients Infected During the Omicron Phase.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionLong COVID is a multisystemic, fluctuating condition inducing a high burden on affected people. Despite the existence of some guidelines, its management remains complicated. We aimed to demonstrate that symptoms after a COVID-19 infection evolve following different trajectories from the initial infection until 24 months after, to identify the determinants of these trajectories, and the quality of life of people in these trajectories.
methodsStudy participants from the Predi-COVID cohort were digitally followed from their acute SARS-CoV-2 infection until a maximum of 24 months. Data from 10 common symptoms collected at study inclusion, and months 12, 15, and 24 awere used to create a total symptom score. Impact of symptoms on quality of life was assessed at month 24 using standardized questionnaires and ad-hoc questions. Latent classes mixed models were used to identify total score symptom trajectories and individual symptoms trajectories.
resultsWe included 555 participants with at least 2 different time points available during follow-up (Baseline and at least one of the M12, M15 or M24 questionnaires). We identified 2 total symptom score trajectories: T1 "Mild symptoms, fast resolution" (N = 376; 67.7%), and T2 "Elevated and persisting symptoms" (N = 179; 32.3%). The main determinants of being in T2 were: older age (OR = 1.86; p = 0.003), to be a woman (OR = 1.81; p = 0.001)), elevated BMI (OR = 3.97; p < 0.001), and the presence of multi comorbidities (OR = 2.67; p = 0.005). Symptoms impacted the quality of life more in T2 than in T1 at 24 months (high fatigue level: 64.8% vs 19.5%, altered respiratory quality of life: 42.6% vs 4.6%, anxiety: 24.1% vs 4.6%, stress: 57.4% vs 35.6%, and bad sleep: 75.9% vs 51.1%).
conclusionA third of our study population was in the T2 "Elevated and persisting symptoms" trajectory, presenting high symptom frequencies up to 24 months after initial infection, with a significant impact on quality of life. This work underlined the urgent need to better identify individuals most vulnerable to long-term complications to develop tailored interventions for them.
trial registrationClinicaltrials.gov NCT04380987 (date of registration: 2020-05-07).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.